Article Search

SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer

September 1, 2026

This is another nail in the anti-TIGIT coffin. In more than 500 patients with untreated PD-L1–high non–small cell lung cancer (NSCLC), adding tiragolumab to atezolizumab missed both primary endpoints, and the numerical progression-free survival (PFS) and overall survival (OS) gains never reached significance. What it did add was toxicity: twice the grade 3–4 adverse events (AEs) and more discontinuations. Together with the other failed TIGIT programs, this pretty much closes the door on chemo-free anti-TIGIT combinations in first-line NSCLC, so single-agent PD-(L)1 or chemo-IO stays the standard for these patients.

Read More »

Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy

September 1, 2026

This looks like a real second-line win in relapsed small-cell lung cancer (SCLC): the B7-H3 ADC tambotatug pelitecan beat topotecan on every endpoint, with median overall survival (OS) of 13 vs 9 mos, median progression-free survival (PFS) of 7 vs 3 mos, and a 59% vs 10% response rate, plus a 32% vs 3% intracranial response rate. It was also easier to tolerate than topotecan, with grade 3 or higher events in 55% vs 78%, though the 5% rate of ILD/pneumonitis (mostly low grade) means we'll need the usual ADC vigilance. The caveats are that this is an interim, open-label analysis with only about 9 mos of follow-up in an all-Chinese population, and the OS sits right next to tarlatamab's 14 mos in DeLLphi-304, so the next debate will be about sequencing these two.

Read More »

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial

August 1, 2026

Combining 177Lu-PSMA-617 with androgen deprivation therapy (ADT) plus androgen receptor pathway inhibitor (ARPI) prolonged radiographic progression-free survival in patients with prostate-specific membrane antigen (PSMA) -positive disease, Radiographic progression-free survival was significantly improved in the 177Lu-PSMA-617 arm vs the control arm, with a 28% reduction in the relative risk of radiographic progression or death (HR 0·72 [95% CI 0·58–0·90]; p=0·0021; dry mouth was the most common side effects. Moving to frontline

Read More »

GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults

August 1, 2026

The cohort included 229 467 patients; 86 422 (37.7%) received glucagon-like peptide-1 receptor agonist (GLP-1RA), while 143 045 (62.3%) received diet or exercise consultation. With a median follow-up of 2 years (interquartile range 1-2 years), the propensity score matching analysis showed a significantly lower incidence of any Obesity Associated Cancers among GLP-1RA users (hazard ratio 0.59, 95% confidence interval 0.53-0.67). Secondary analyses showed that in all subgroups, except for black race, GLP-1RA use was associated with a lower cumulative incidence of OACs. GLP-1 will be studied more often in cancer patients, some practices, already have GLP-1 clinic as part of their cancer care.

Read More »

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial

August 1, 2026

644 patients who are triple-negative breast cancer (TNBC) not candidates for immunotherapy were randomly assigned to receive Dato-DXd (n = 323) or chemotherapy (n = 321). Median progression-free survival (PFS) was 10.8 months with Dato-DXd and 5.6 months with chemotherapy. Median overall survival (OS) was 23.7 months and 18.7 months with Dato-DXd and chemotherapy, respectively HR 0.79; P = 0.029]. Treatment-related adverse events (TRAEs) of grade ≥3 were reported in 105 (33%) and 89 (29%) patients who received Dato-DXd and chemotherapy, respectively, they were more treatment discontinuation in the chemotherapy arm secondary to treatment related adverse events in 14 (4%) and 23 (7%) patients. There were no treatment-related deaths in either arm. New standard of care? Recall this is on patients not eligible for immunotherapy.

Read More »

Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study

August 1, 2026

Epidermal growth factor receptor (EGFR) and MET are overexpressed in recurrent/metastatic (R/M) head/neck squamous cell cancer (HNSCC).
Subcutaneous amivantamab administered every 3 weeks in participants with non-human papillomavirus R/M HNSCC after PD-(L)1 inhibitor and platinum-based chemotherapy. prior anti EGFR and HPV positive patients were excluded. In 102 participants, blind independent central review assessed objective response rates (ORRs) was 42% (around 20% for second line chemotherapy or cetuximab) the complete response rate was 15%. At a median follow-up of 11.8 months, median progression-free survival (PFS) and overall survival (OS) were 6.8 months and 12.5 months respectively. A non-chemotherapy option for HPV negative patients with promising outcome. Toxicity can still be an issue with those pts

Read More »

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial

August 1, 2026

Patients were randomized to Rux placebo vs Rux and selinexor. At week 24, spleen volume reduction ≥35% (SVR35) was achieved in 49.8% of the selinexor plus ruxolitinib group vs 28.0% of the placebo plus ruxolitinib group. Symptom scores improved from baseline in both groups (−9.9 selinexor plus ruxolitinib, −10.9 placebo plus ruxolitinib), with no significant between-group difference will need long term follow up to assess the symptoms relief and the clonal regression.

Read More »

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

August 1, 2026

Progression-free survival (PFS) was higher in the Sun group vs chemotherapy, 10.3 m vs 7.5 m with HR of .65 with higher responses (58.9% vs 31.1%) diarrhea high CK and anemia were the most common side effects. The issue is that amivan was not part of treatment and compared to chemotherapy ami in addition to chemotherapy had 11m PFS also in this trial few had brain mets so no evaluation for CNS protection or treatment. But an oral agent in patients who don’t want to come to the office often.

Read More »

Keyword Search

  • Article Search

  • Cancer Types

  • Month Contributed

  • Show FCS Articles Only

  • Sort Order

  • Number of Posts